Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal bleeding in the cardiac operating room: An observational study of interrater reliability between anesthetists and surgeons.

JTCVS open·2026
Same author

Diagnostic relevance of angiography-derived coronary microcirculatory resistance in sudden cardiac death.

Quantitative imaging in medicine and surgery·2026
Same author

Echocardiographic risk stratification in heart failure with post-capillary pulmonary hypertension: prognostic value of LAVI and TAPSE/PASP.

European heart journal. Cardiovascular Imaging·2026
Same author

Medium-term outcomes and prognostic factors after transcatheter paravalvular leak closure: an international prospective multicentre registry.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Outcomes of transcatheter patent ductus arteriosus closure in infants weighing 2 to 6 kg.

Revista espanola de cardiologia (English ed.)·2025
Same author

Self-expandable Venus P-valve in Patient with Transposition of Great Arteries and Arterial Switch Operation.

Pediatric cardiology·2025

Related Experiment Video

Updated: May 22, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

[Peripartum cardiomyopathy: A multiple entity].

Gérald Vanzetto1, Alix Martin, Hélène Bouvaist

  • 1Centre hospitalier universitaire de Grenoble, cliniques universitaires de cardiologie, BP 217, 38043 Grenoble cedex 7, France. gvanzetto@chu-grenoble.fr

Presse Medicale (Paris, France : 1983)
|May 5, 2012
PubMed
Summary

Peripartum cardiomyopathy (PPCMP) is a heart failure condition during pregnancy or postpartum. Early diagnosis and intensive care are crucial, with treatments similar to other heart failures, but bromocriptine shows promise.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

Related Experiment Videos

Last Updated: May 22, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

Area of Science:

  • Cardiology
  • Obstetrics
  • Maternal-Fetal Medicine

Background:

  • Peripartum cardiomyopathy (PPCMP) is a rare but serious heart condition affecting women during late pregnancy or after childbirth.
  • It is characterized by new-onset heart failure with left ventricular dysfunction, lacking a clear underlying cause or prior heart disease.
  • The incidence ranges from 1/1000 to 1/4000 births, highlighting its significance in obstetric and cardiac care.

Purpose of the Study:

  • To define peripartum cardiomyopathy (PPCMP) and its diagnostic criteria.
  • To outline the pathophysiological mechanisms, clinical presentation, and diagnostic approaches for PPCMP.
  • To discuss current therapeutic strategies and long-term outcomes for patients with PPCMP.

Main Methods:

  • Diagnosis relies on clinical presentation of heart failure and echocardiographic evidence of left ventricular dysfunction (ejection fraction <0.45).
  • Exclusion of other known cardiac conditions and etiologies is essential for diagnosis.
  • Patient management involves referral to specialized cardiac care centers for intensive monitoring and treatment.

Main Results:

  • PPCMP is multifactorial, involving potential immunologic, hormonal, and viral factors.
  • Echocardiography is critical for diagnosis, prognosis, and guiding treatment decisions.
  • While standard heart failure therapies are used, ACE-inhibitors are contraindicated before delivery; anticoagulation is vital due to high thrombo-embolic risk.

Conclusions:

  • Approximately 50% of patients recover left ventricular function, while the other half experience persistent dysfunction, with 25% developing chronic heart failure.
  • Bromocriptine, a prolactin inhibitor, has shown promising results in reducing morbidity and mortality, warranting further large-scale trials.
  • Prompt diagnosis, intensive care, and appropriate management are essential for improving outcomes in peripartum cardiomyopathy.